PainReform (PRFX) Receives a Buy from Maxim Group

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on PainReform (PRFX – Research Report). The company’s shares opened today at $0.80.

According to TipRanks, Rahman is an analyst with an average return of -9.7% and a 32.86% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Palisade Bio, Viking Therapeutics, and PainReform.

The analyst consensus on PainReform is currently a Moderate Buy rating.

PRFX market cap is currently $1.98M and has a P/E ratio of -0.10.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PainReform (PRFX) Company Description:

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company’s product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.